International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease
International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease
Aim of the study is to gain more knowledge about efficacy and safety of Neovasculgen® in daily clinical practice and obtain information about the quality of life in patients treated with Neovasculgen®.
This is an open, controlled, prospective, comparative, multicentre study design. All patients received standard conservative therapy for chronic limb ischemia without cilostazol and prostaglandins and without surgical or endovascular vessel reconstruction. Surgical and endovascular vessel reconstruction was unsuitable for all of the patients
Inclusion Criteria:
Exclusion Criteria:
Barnaul, Altayskiy Kray 656038, Russia
Blagoveshchensk, Amur Oblast 675028, Russia
Ulan-Ude, Buryatiya Republic 670031, Russia
Chelyabinsk, Chelyabinsk Oblast 454071, Russia
Irkutsk, Irkutsk Oblast 664046, Russia
Irkutsk, Irkutsk Oblast 664079, Russia
Kemerovo, Kemerovo Oblast 650066, Russia
Kemerovo, Kemerovskaya 650002, Russia
Khabarovsk, Khabarovskiy Kray 680009, Russia
Tyumen, Khanty-Mansiysk District 625023, Russia
Krasnodar, Krasnodarskiy Kray 350086, Russia
Krasnoyarsk, Krasnoyarsk Region 660062, Russia
Moscow, Moscow Oblast 129110, Russia
Novosibirsk, Novosibirsk Oblast 630047, Russia
Novosibirsk, Novosibirsk Oblast 630117, Russia
Vladivostok, Primorskiy (Maritime) Kray 690091, Russia
Rostov-on-Don, Rostovskaya 344022, Russia
Samara, Samara Oblast 443095, Russia
Tolyatti, Samara Rigion 445023, Russia
Saint Petersburg, Sankt-Peterburg 192242, Russia
Kazan', Tatarstan Republic 420064, Russia
Yaroslavl, Yaroslavl Oblast 150023, Russia